Drug intelligence / Profile preview

Y-6

Development stage: Unknown
Lead developer: Fourth Affiliated Hospital of Guangxi Medical University
Modality: Small Molecules
Administration: Sublingual

Overview

Y-6 is an investigational small molecule neuroprotective agent currently in Phase 1 clinical development for the treatment of acute ischemic stroke. Formulated as a sublingual tablet, it is designed for rapid administration in the acute setting to minimize neuronal damage. The drug is sponsored by Liuzhou Workers Hospital and is classified as a Class 1 innovative drug in China. Mechanistically, Y-6 functions as a free radical scavenger, neutralizing reactive oxygen species (ROS) that are generated during ischemia and reperfusion, thereby protecting brain tissue from oxidative stress-induced apoptosis and necrosis.

Other names: Y-6 sublingual tabletsY6 sublingual tabletsY 6 sublingual tablets

Beyond the preview

Go deeper on Y-6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y-6.

Explore the full profile